Prosecution Insights
Last updated: August 16, 2026

Oxford University Innovation Limited

32 pending office actions • 24 art units • 31 examiners • 0 of 32 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days

Portfolio Summary

32
Total Pending OAs
16
Non-Final OAs
16
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
0
Due this week
3
Due this month
2
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)Due ≤ 30 days (3)Due ≤ 60 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

11
Hard (34%)
14
Medium (44%)
6
Easy (19%)
1
Unknown (3%)

Rejection Statute Mix

BucketCases
§101 + other4 (12%)
§103 only11 (34%)
§102 only1 (3%)
§112 only5 (16%)
Double-patenting only1 (3%)
Double-patenting + other2 (6%)
Multi-statute (no §101)7 (22%)
No statute on record1 (3%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

25
Life Sciences
78% of docket
0
Information Tech
0% of docket
1
Communications
3% of docket
2
Semiconductors
6% of docket
3
Mechanical / Eng
9% of docket
1
Business / Other
3% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

320 h
Manual time on pending OAs
64 h
Time saved (low, 20%)
112 h
Time saved (mid, 35%)
2.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BATES, KEENAN ALEXANDER 2 44.8% +76.5%
BALL, JOHN C 1 78.8% +16.2%
VASISTH, VISHAL V 1 72.3% +33.7%
MUTCHLER, CHRISTOPHER JOHN 1 55.4% +22.2%
VU, PHU 1 85.3% +9.6%
PEDAPATI, CHANDHANA 1 74.2% +21.8%
RZECZYCKI, PHILLIP MATTHEW 1 63.0% +39.1%
ROE, JESSEE RANDALL 1 76.3% +7.8%
PAULUS, ERIN VIRGINIA 1 25.0% +92.3%
CAREY, MICHAEL JAMES 1 83.6% +12.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18708552 OPTICAL MULTIPLICATION SYSTEM AND OPTICAL MULTIPLICATION METHOD VU, PHU

Hard Cases (11)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17624764 METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS SPANGLER, JOSEPH RANKIN 341d overdue
18279624 BIOMARKER COUNTS, GARY W 19d overdue
17781738 INTRAORAL DEVICE SHOSTAK, ANDREY 10d overdue
15963271 DIAGNOSING MULTIPLE SCLEROSIS DUNN, MCKENZIE A 9d
18727730 DECOMPOSITION OF POLYOLEFINS VASISTH, VISHAL V 30d
18039846 OLIGONUCLEOTIDES OLSON, ALEXANDRA NADINE 33d
17914936 METHOD FOR FORMING COATED HYDROGEL BEADS WASHVILLE, JEFFREY D 36d
18553295 Gene Therapy for Retinal Disease PAULUS, ERIN VIRGINIA

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18617722 APPARATUS LOCALISATION PEDAPATI, CHANDHANA 15d
18727730 DECOMPOSITION OF POLYOLEFINS VASISTH, VISHAL V 30d
19038507 MOLECULAR HOPPER BALL, JOHN C
18709043 SYSTEMS AND METHODS FOR MEASURING A RESPONSE OF A SUBJECT TO AN EVENT MUTCHLER, CHRISTOPHER JOHN
18563606 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES RZECZYCKI, PHILLIP MATTHEW
18553295 Gene Therapy for Retinal Disease PAULUS, ERIN VIRGINIA
18282561 MODULATING WAKEFULNESS AND AROUSAL CAREY, MICHAEL JAMES
18021691 PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY BATES, KEENAN ALEXANDER

Top Art Units

Art UnitApps
1631 4
1678 2
1643 2
1672 2
1653 2
1771 1
3796 1
2871 1
2669 1
1625 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
19038507 MOLECULAR HOPPER BALL, JOHN C DP Non-Final OA Pending Jan 27, 2025
18727730 DECOMPOSITION OF POLYOLEFINS VASISTH, VISHAL V 1771 §103§112Other Final Rejection 30d Pending Jul 10, 2024
18709043 SYSTEMS AND METHODS FOR MEASURING A RESPONSE OF A SUBJECT TO AN EVENT MUTCHLER, CHRISTOPHER JOHN 3796 §112 Final Rejection Pending May 10, 2024
18708552 OPTICAL MULTIPLICATION SYSTEM AND OPTICAL MULTIPLICATION METHOD VU, PHU 2871 §103 Non-Final OA Pending May 08, 2024
18617722 APPARATUS LOCALISATION PEDAPATI, CHANDHANA 2669 §103 Non-Final OA 15d Pending Mar 27, 2024
18563606 2-CARBOXYL-INDOLE INHIBITORS OF METALLO-BETA-LACTAMASES RZECZYCKI, PHILLIP MATTHEW 1625 §103§112DP Non-Final OA Pending Nov 22, 2023
18514737 NICKEL-BASED ALLOY ROE, JESSEE RANDALL 1759 Other Non-Final OA Pending Nov 20, 2023
18553295 Gene Therapy for Retinal Disease PAULUS, ERIN VIRGINIA 1631 §101§102 Non-Final OA Pending Sep 29, 2023
18282561 MODULATING WAKEFULNESS AND AROUSAL CAREY, MICHAEL JAMES 3700 §102§103§112 Non-Final OA Pending Sep 18, 2023
18279624 BIOMARKER COUNTS, GARY W 1678 §101§102§112 Final Rejection 19d overdue Pending Aug 31, 2023
18451671 DETECTION OF ACUTE MYELOID LEUKAEMIA CHATTIN, AMY MARIE 1643 §102 Final Rejection Pending Aug 17, 2023
18272115 VACCINE COMPOSITIONS GRIZER, CASSANDRA SENN 1672 §102§103§112 Final Rejection Pending Jul 13, 2023
18272114 TRANSDERMAL VACCINE STOICA, ELLY GERALD 1647 §112 Non-Final OA Pending Jul 13, 2023
18039846 OLIGONUCLEOTIDES OLSON, ALEXANDRA NADINE 1684 §102§103§112Other Non-Final OA 33d Pending Jun 01, 2023
18021691 PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY BATES, KEENAN ALEXANDER 1631 §103 Final Rejection Pending Feb 16, 2023
18021675 METHOD OF MAKING RECOMBINANT AAVS BATES, KEENAN ALEXANDER 1631 §103DP Final Rejection Pending Feb 16, 2023
18015426 METHOD OF TREATMENT OF CONGENITAL MYASTHENIC SYNDROME USING DOK7 GENE OR POLYPEPTIDE KELLY, ROBERT M 1638 §112 Non-Final OA 16d overdue Pending Jan 10, 2023
18057359 EXOSOMES COMPRISING THERAPEUTIC POLYPEPTIDES HASAN, KHALEDA B 1636 §103 Non-Final OA Pending Nov 21, 2022
17999358 ENHANCEMENT OF PRODUCTIVITY IN C3 PLANTS STOCKDALE, JESSICA NICOLE 1663 §101§102§103§112 Non-Final OA Pending Nov 18, 2022
17924695 CHIMAERIC PROTEINS AND THERAPEUTIC AGENTS NATARAJAN, MEERA 1643 §112 Non-Final OA Pending Nov 11, 2022
17920561 METHOD OF REDUCING AND RECYCLING OXIDIZED FLAVIN COFACTORS BOWERS, ERIN M 1653 §103 Final Rejection 80d overdue Pending Oct 21, 2022
17919907 PROCESS AND CATALYST ZHANG, KELING NMN 1732 §103 Final Rejection Pending Oct 19, 2022
17914936 METHOD FOR FORMING COATED HYDROGEL BEADS WASHVILLE, JEFFREY D 1766 §102§103 Final Rejection 36d Pending Sep 27, 2022
17796303 Process for Making Adenoassociated Viral Vectors VIJAYARAGHAVAN, JAGAMYA NMN 1633 §112 Non-Final OA Pending Jul 29, 2022
17781738 INTRAORAL DEVICE SHOSTAK, ANDREY 3791 §102§103§112Other Final Rejection 10d overdue Pending Jun 02, 2022
17775602 METHOD OF ISOLATING A SELECTED POPULATION OF EXOSOMES MOSS, NATALIE M 1653 §103 Non-Final OA Pending May 10, 2022
17626833 PROCESS FOR PRODUCING A GASEOUS PRODUCT COMPRISING HYDROGEN DOWNES, NATHANAEL JASON 1794 §103 Final Rejection 73d overdue Pending Jan 13, 2022
17624764 METHODS FOR DIAGNOSING MULTIPLE SCLEROSIS SPANGLER, JOSEPH RANKIN 1656 §101§103§112 Final Rejection 341d overdue Pending Jan 04, 2022
17618648 OPTICAL DEVICES AND METHODS TAVLYKAEV, ROBERT FUATOVICH 2896 §103 Non-Final OA Pending Dec 13, 2021
17291879 COMPOSITIONS AND METHODS KINSEY WHITE, NICOLE ERIN 1672 §103 Final Rejection 35d overdue Pending May 06, 2021
17278679 EDITING OF HAEMOGLOBIN GENES SPENCER, ANDREA LYNNE MORRIS 1631 §103Other Final Rejection Pending Mar 23, 2021
15963271 DIAGNOSING MULTIPLE SCLEROSIS DUNN, MCKENZIE A 1678 §103§112 Final Rejection 9d Pending Apr 26, 2018

Managing Oxford University Innovation Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month